Ji Eunjeong, Kim Kidong, Lee Banghyun, Hwang Sung Ook, Lee Hee Joong, Lee Kyungjin, Lee Minkyung, Kim Yong Beom
Medical Research Collaborating Center, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si 13620, Korea.
Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si 13620, Korea.
Cancers (Basel). 2022 Jun 23;14(13):3090. doi: 10.3390/cancers14133090.
The effect of postoperative hormone replacement therapy (HRT) on survival in women with ovarian cancer remains unclear. This study aimed to investigate the impact of postoperative HRT on survival in women with ovarian cancer using the nationwide cohort study. Women aged ≤60 and diagnosed with ovarian cancer that received primary surgery were followed-up for 5.6 ± 2.9 years. Mean ages of women administered HRT (the HRT group; n = 263) or not administered HRT (the control group; n = 1521) were 41.5 ± 8.5 and 41.0 ± 11.4 years, respectively. After adjustment for covariables, OS was significantly greater in the HRT group (HR 0.618; 95% CI 0.414−0.922; p = 0.018). Kaplan−Meier curve analysis showed OS was significantly higher in the HRT group (85.3% vs. 76.6%; p = 0.016). The ratio of women with HRT to women without HRT increased significantly with time (restricted mean survival times for OS, p < 0.001). In addition, OS was significantly greater for those that received HRT for >5 years than for those that received HRT for ≤0.5 years (HR 0.234; 95% CI 0.059−0.936; p = 0.040). Postoperative HRT improved survival among women with ovarian cancer. The impact of HRT on survival increased with time and treatment duration.
术后激素替代疗法（HRT）对卵巢癌女性患者生存率的影响尚不清楚。本研究旨在利用全国队列研究调查术后HRT对卵巢癌女性患者生存率的影响。对年龄≤60岁且接受了初次手术的卵巢癌女性患者进行了5.6±2.9年的随访。接受HRT的女性（HRT组；n = 263）和未接受HRT的女性（对照组；n = 1521）的平均年龄分别为41.5±8.5岁和41.0±11.4岁。在对协变量进行调整后，HRT组的总生存期（OS）显著更长（风险比[HR]0.618；95%置信区间[CI]0.414 - 0.922；p = 0.018）。Kaplan - Meier曲线分析显示，HRT组的OS显著更高（85.3%对76.6%；p = 0.016）。接受HRT与未接受HRT的女性比例随时间显著增加（OS的受限平均生存时间，p < 0.001）。此外，接受HRT超过5年的患者的OS显著高于接受HRT≤0.5年的患者（HR 0.234；95% CI 0.059 - 0.936；p = 0.040）。术后HRT改善了卵巢癌女性患者的生存率。HRT对生存率的影响随时间和治疗持续时间增加。
